Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
611 hedge funds and large institutions have $21.8B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 228 increasing their positions, 215 reducing their positions, and 46 closing their positions.
109% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 46
42% more call options, than puts
Call options by funds: $123M | Put options by funds: $86.3M
7% more funds holding
Funds holding: 572 → 611 (+39)
6% more repeat investments, than reductions
Existing positions increased: 228 | Existing positions reduced: 215
1% less capital invested
Capital invested by funds: $22B → $21.8B (-$248M)
30% less funds holding in top 10
Funds holding in top 10: 30 → 21 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$176M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$144M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$120M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$109M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$77.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$191M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$164M |
| 3 |
Renaissance Technologies
New York
|
-$106M |
| 4 |
SI
Scout Investments
Kansas City,
Missouri
|
-$92.1M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$85.7M |
HZNP Hedge Fund Activity: Q4 2021 in Review
611 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2021, worth a combined $21.8B — down 1.1% from $22B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new HZNP positions and 46 closed out — a net gain of 50 holders — while 228 added to existing stakes and 215 trimmed.
The largest buyer was Marshall Wace, adding an estimated $176M. The largest seller was Adage Capital Partners, cutting an estimated $191M.
- 611 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2021, up from 572 in Q3 2021.
- Funds reported $21.8B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2021, down 1.1% quarter-over-quarter.
- 96 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2021 and 46 closed out, a net change of +50 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2021 was Marshall Wace, an estimated $176M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2021 was Adage Capital Partners, an estimated $191M sold.
Based on aggregated 13F filings for Q4 2021.